BioMarin Pharmaceuticals BMRN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's retained earnings?
- BioMarin Pharmaceuticals (BMRN) reported retained earnings of $259.73M in Q1 2026.
- How has BioMarin Pharmaceuticals's retained earnings changed year-over-year?
- BioMarin Pharmaceuticals's retained earnings increased by 2983.0% year-over-year, from -$9.01M to $259.73M.
- What is the long-term trend for BioMarin Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's retained earnings has grown at a -29.1% compound annual growth rate (CAGR), from -$861.61M to $154.21M.
- What does retained earnings mean?
- The total profit the company has kept and reinvested in the business since it started.
- How do you interpret retained earnings?
- A growing balance indicates consistent profitability and successful reinvestment, while a negative balance indicates accumulated historical losses.
- How does retained earnings compare across companies?
- High-growth biotech firms often have negative retained earnings due to heavy R&D spending; mature firms show positive, growing balances.